Die Allianz baut auf einer 2017 geschlossenen Kooperations- und Optionsvereinbarung auf. Im Rahmen der erweiterten Vereinbarung erhält Kaken die kommerziellen Rechte für NM26-2198 in Japan, China, Südkorea, Taiwan, Singapur und Hongkong, während Numab die kommerziellen Rechte für die USA, Europa und den Rest der Welt behält. Die Parteien werden NM26-2198 gemeinsam entwickeln, wobei Kaken den Grossteil der weltweiten Entwicklungskosten bis zum klinischen Wirksamkeitsnachweis trägt. Bei erfolgreicher Kommerzialisierung von Produkten, die aus der Allianz hervorgehen, wird Kaken bestimmte Zahlungen von Numab bis zu einer Obergrenze erhalten, die auf der Grundlage früherer F&E-Zahlungen von Kaken an Numab berechnet wird.
Team von VISCHER
Das Team von VISCHER wurde von Dr. Stefan Kohler (IP/Life Sciences) und Christoph Niederer (Tax) geleitet.
Über die Transaktion
Numab informierte wie folgt über die spannenden Life Science Transaktion:
Numab Therapeutics AG today announced the formation of a global co-development and regional licensing agreement with Kaken Pharmaceutical for the company’s novel multispecific anti-inflammatory drug candidate NM26- 2198, which blocks three key pathways in the pathophysiology of atopic dermatitis.
The alliance builds on a collaboration and option agreement established in 2017. Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world. The parties will jointly develop NM26-2198 with Kaken covering the majority of global development costs up to clinical proof-of-concept. Upon successful commercialization of products resulting from the alliance, Kaken will receive certain payments from Numab up to a cap that is calculated based on previous R&D payments made by Kaken to Numab.
“Today’s news puts our second proprietary key pipeline asset NM26-2198 on a very promising path for value generation and accelerated global development. The alliance with Kaken Pharmaceutical is in line with our Asia regional partnering strategy and follows the structure of our previous deal with CStone Pharmaceutical on our lead oncology asset NM21-1480,” said David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics.
About Numab Therapeutics
Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH technology platform, we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes. For further information, visit www.numab.com.
About Kaken Pharmaceutical
Kaken Pharmaceutical Co., Ltd. (KAKEN) is a specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics and dermatology. KAKEN concentrates its R&D resources in areas such as the immune system, the nervous system, and infectious diseases. KAKEN’s ongoing quest is to Bringing Smiles to Everyone. For this purpose, KAKEN strives to improve the quality of life of patients through the development and distribution of superior pharmaceuticals. For further information, visit http://www.kaken.co.jp.
